Compare Johnson & Johnson (JNJ) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Johnson & Johnson trades at $260.7 (market cap $626.09B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.31. The key difference: Johnson & Johnson pays a 2.06% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and Johnson & Johnson is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| JNJ | YMAG | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | Income / Options Overlay |
52-Week High | $267.24 | $15.98 |
52-Week Low | $172.78 | $10.76 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
YMAG trades at $11.29, down 2.59% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividends, with recent payouts ranging from $0.07 to $0.40, highlighting its income-focused strategy. News coverage emphasizes distribution announcements and NAV stability concerns amid earnings volatility.
Outlook hinges on sustained option income generation, but risks include NAV decay from call spreads and market volatility. Analyst sentiment is mixed, with some viewing it as a tactical buy in rangebound markets. Key risks are earnings-driven NAV swings and competitive ETF structures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
